Biotech Values

[DewDiligence]

Phase-2b RA Data for PFE’s Oral JAK Inhibitor

PFE reported 24-week mono and combo data for CP-690,550 at the
ACR conference in Philadelphia today. I reformatted the two data
tables below in a way that I think makes them easier to comprehend.
For further info, please see PFE’s PR at:
http://finance.yahoo.com/news/CP690550-Pfizers-Oral-JAK-bw-2044269467.html/print?x=0 .


FORMATTING LEGEND:
Italic: p-value between 0.01 and 0.05.
Underlined: p-value between 0.0001 and 0.01.
Bold: p<=0.0001.

 
            24-WEEK MONOTHERAPY DATA 
 Trial                                  DAS28  
  Arm     ACR20     ACR50     ACR70   Remission 
  1mg     24.1%      7.4%      5.6%      5.8%  
  3mg     37.3%     27.5%     13.7%     13.7%  
  5mg     51.0%     34.7%     20.4%     14.6%  
 10mg     65.6%     44.3%     37.7%     21.3%  
 15mg     66.7%     54.4%     33.3%     21.1%  
 Placebo  25.4%     10.2%      6.8%      1.8%  
  
  
        24-WEEK COMBINATION-THERAPY DATA 
 Trial                                  DAS28  
  Arm     ACR20     ACR50     ACR70   Remission 
  1mg     41.4%     31.4%     20.0%     13.2%  
  3mg     52.9%     27.9%     19.1%     23.9%  
  5mg     47.9%     33.8%     19.7%     28.6%  
 10mg     55.4%     35.1%     17.6%     29.6%  
 15mg     58.7%     44.0%     30.7%     29.7%  
 20mg     52.5%     38.8%     23.8%     22.8% 
 Placebo  34.8%     23.2%      7.3%     10.5%